Prof Rana Hinman is a physiotherapist who leads research focussed on improving the health of people living with osteoarthritis. Her multi‐disciplinary research produces and translates innovative, robust and pragmatic evidence about non‐drug, non‐surgical approaches to managing osteoarthritis symptoms, including novel methods of service delivery. Her research has informed Australian and international clinical practice guidelines, as well as national osteoarthritis research strategy, policy and models of care.

Professor Hinman has approximately 250 peer‐reviewed papers, has made sustained contributions to peer review (including Editorial Boards of leading physiotherapy journals and NHMRC grant review) and has received national and institutional awards for excellence in mentoring research students.

Professor Harriet Hiscock is internationally renowned for her expertise and leadership in sleep and mental health research. She leads world class health services research to develop, test and implement evidence-based interventions to improve the quality, accessibility, and value of healthcare for paediatric common, high burden conditions. As a clinician researcher, she has published over 180 peer reviewed papers and her sleep interventions have been implemented in the UK, Netherlands, USA, and New Zealand.

Professor Hiscock holds a NHMRC Practitioner Fellowship, leads the NHMRC Centre of Research Excellence in Childhood Adversity, and is inaugural Director of Australia’s only paediatric health services research unit.

Professor David Huang is a biomedical researcher who made fundamental research discoveries on programmed cell suicide (apoptosis) that laid the foundations for the discovery and development of a novel class of anti-cancer drugs. He made critical contributions towards revealing how BCL2, often overactive in blood cancers, and its relatives block cell death thereby uncovering how BCL2 could be targeted in cancer cells. In collaboration with industry partners, this work led to the development of venetoclax to target BCL2. Venetoclax has proven highly effective and is now approved in Australia and other jurisdictions for patients with some types of leukaemias and lymphomas.

Professor Karin Leder is an infectious disease phsician, Head of Infectious Disease Epidemiology (Monash University) and Director of Travel Medicine and Immigrant Health (Royal Melbourne Hospital). As a world leader in disease spread across international borders, her research outputs have changed global surveillance prioritities and clinical management of infections among mobile populations. She also leads a multidisciplinary research program to improve water-sanitation management, reduce health impacts from exposure to environmental microbial contamination and mitigate adverse climate change effects via introduction of sustainable technology into resource-poor settings.

Professor Leder is renowned for mentoring a new generation of independent clinician-researchers.